Certolizumab pegol 400 mg monthly in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the response or have developed intolerance to infliximab: an open-label, multi-center, single-cohort study to evaluate efficacy, safety and onset of action To assess the clinical efficacy of subcutaneous certolizumab pegol 400 mg at week 6, following administration at 0, 2 and 4 weeks for the treatment of signs and symptoms of active Crohn’s Disease (CDA...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune